Sarepta Therapeutics (SRPT) Terminates Chief Science Officer As It Heads Toward Drug Approval

Sarepta Therapeutics (SRPT) Terminates Chief Science Officer As It Heads Toward Drug Approval

Sarepta Therapeutics disclosed in a federal filing that on Tuesday its chief scientific officer was terminated from his position.

Arthur Krieg was hired to the company just six months ago as senior vice president and chief scientific officer. The filing with the Securities and Exchange Commission early Thursday morning gave no reason for the termination, and the company did not immediately respond to an email seeking comment on Thursday morning. 

 

Suggested Articles

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.

Vertex is keeping mum on exact details but, as with the rest of its biopharma peers, is seeing trial disruption due to the COVID-19 pandemic.

Companies including Novartis and Pfizer are contributing to the joint response through actions including the sharing of proprietary compounds